Tunisian artificial intelligence (AI) startup, Instadeep has been totally acquired by Mainz based German biotechnology company, BioNTech after the medical powerhouse agreed to pay a total sum of £582 million ($682 million) to acquire 100% Instadeep shares.
BioNTech has in the last few years developed and manufactured active immunotherapies for patient-specific approaches to the treatment of diseases and has created one of the world’s most effective COVID-19 vaccines during the pandemic. The company will make an upfront payment of cash and unspecified BioNTech shares worth £362 million, and a balance of £200 million payable based on InstaDeep’s future performance.
This would not be the first time that the two companies will have something to do together, as it would be recalled that BioNTech made an active participation in InstaDeep’s Series A last January, and indication of an overall good partnership history between the two companies.
Also in November 2020, InstaDeep and BioNTech initiated a joint AI Innovation Lab that would use the latest advances in AI and ML technology to develop novel medicines for a range of cancers and infectious diseases. The two companies have jointly developed multiple end-to-end AI-based applications including the development of an early warning System to detect and monitor high-risk SARS-CoV-2 variants.
The CEO and co-founder of BioNTech, Uğur Sahin, while speaking on the acquisition, said: “The acquisition of InstaDeep allows us to incorporate the rapidly evolving AI capabilities of the digital world into our technologies, research, drug discovery, manufacturing, and deployment processes.”
InstaDeep has developed from its founding dreams as a tech startup founded by Karim Beguir and Zohra Slim in Tunisia in 2014, to becoming a renowned AI company in 2015, with the company growing to a 240-employee institution, with offices in London, Tunis, Paris, Dubai, Lagos, and Cape Town.
InstaDeep CEO and Co-Founder, Karim Beguir while speaking on the fusion with BioNTech said
“We are very excited to join forces and become one team with BioNTech, with whom we share the same culture of deep tech innovation and focus on positive human impact. Together, we envision building a world leader that combines biopharmaceutical research and AI with the aim to design next-generation immunotherapies that enhance medical care—thus, helping fight cancer and other diseases.”
Prior to the agreement, InstaDeep on its part had raised a sum of $107 million, while it also raised an undisclosed funding from Plug and Play and some angel investors.
The new acquisition by BioNTech is the biggest of its kind in Africa, will become sealed in the first half of 2023, subject to customary closing conditions and regulatory approvals.
The implication will be that InstaDeep will operate as a UK-based global subsidiary of BioNTech while ir continues with serving its clients around the world.
Ayoola Faseyi, an Abuja based Journalist with interest in Technology and Politics. He is a versatile writer with articles in many renowned News Journals.
He is the Co-Founder of media brand, The Vent Republic.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
